From Yahoo Finance: 2025-05-14 09:14:00

Benchmark has lowered Harvard Bioscience’s price target to $3 from $4.50 due to challenges in end-user markets for biomedical research related to China tariffs, NIH funding, and biopharmaceutical research activity. Despite near-term uncertainty, management remains optimistic about the company’s 2025 prospects for newly launched products.

For more real-time, market-moving financial news, visit TheFly.

To see insider trading stocks on TipRanks, click the link provided.

For more information on Harvard Bioscience, check out the Disclaimer & Disclosure and Report an Issue sections on TipRanks.

Read more: Harvard Bioscience price target lowered to $3 from $4.50 at Benchmark